<DOC>
	<DOCNO>NCT01529528</DOCNO>
	<brief_summary>This trial evaluate efficacy safety CWP-0403 100 mg 200 mg twice daily compare placebo type 2 diabetic patient inadequate glycemic control diet therapy combination diet exercise therapy .</brief_summary>
	<brief_title>A Study Efficacy Safety CWP-0403 Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 DM patient Subjects could n't control blood glucose despite dietary exercise therapy 6 week screen visit FPG â‰¤ 270mg/dL screen visit Patients consent participate trial write Informed Consent Form Type 1 DM secondary diabetes Subjects administrate insulin need insulin therapy History oral antihyperglycemic drug within 6 week screen visit Body mass index &lt; 20 kg/m2 &gt; 40.0kg/m2 Subjects assessed inappropriate trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CWP-0403</keyword>
	<keyword>type 2 DM</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase 3</keyword>
</DOC>